The molecular mechanisms and biology of cellular senescence in human melanocytes are discussed, including similarities to and differences from senescence in fibroblasts and other cell lineages. Special reference is made to the fact that the known melanoma susceptibility genes in the human, Inhibitor A of [cyclin-dependent] kinase 4-alternative reading frame (INK4A-ARF) and cyclindependent kinase 4, are involved in the regulation of cellular senescence, and possible reasons why this should be so. Based on the evidence including growth and survival kinetics of human and mouse melanocytes carrying germline deficiencies in the INK4A sequence, it is suggested that an 'M0' or p16/RB-dependent form of senescence may be particularly important in melanocytes. A speculative model is proposed, relating current concepts of early melanoma progression to the processes of cellular senescence and immortalization. This includes the suggestion that moles or nevi are senescent clones of melanocytes.
Introduction
It is remarkable that all of the three melanoma susceptibility genes identified so far -INK4A, CDK4 and ARF -are involved in the process of cellular senescence. Senescence is the loss of ability to proliferate seen in most normal somatic cells after a limited number of divisions, and is now recognized as a major barrier to the development of cancers in any mammalian cell lineage (reviews Wynford-Thomas, 1999; Artandi and DePinho, 2000; Sherr, 2001) .
However, it is far from obvious why components in cellular senescence should have some particular importance for melanoma. Accordingly, one central aim of this article is to analyse whether there may be any specific connection between cellular senescence and melanoma. Information will be presented first on the immediate signalling pathways in which these genes are involved, and then their contribution to cellular senescence, followed by an analysis of the specific features of senescence in human melanocytes. Lastly, the possible connections between senescence, melanoma susceptibility and melanoma progression will be discussed.
Melanoma susceptibility genes and their cellular functions
This subject will be considered further in the chapter by Hayward, but needs to be introduced in the present context. The first-identified and best-known locus associated with melanoma susceptibility in humans is found on chromosome 9p21 and is known variously as cyclin-dependent kinase inhibitor 2A (CDKN2A), multiple tumor suppressor 1 (MTS1) or INK4A-ARF (for reviews, see Ruas and Peters, 1998; Sharpless and DePinho, 1999; Hayward, 2000; Rocco and Sidransky, 2001 ). The last name reflects the unusual property that this locus encodes two distinct protein products that start from different first exons but share some coding sequence in two different reading frames. Both proteins are suppressors of cell proliferation, and both are established as important tumor suppressors in humans, being mutated in a substantial range of sporadic tumor types (Ruas and Peters, 1998) . One is the 16-kDa protein p16, or Inhibitor A of (cyclin-dependent) kinase 4 (INK4A -more below), and the other is known as ARF after its alternative reading frame (also called p19
Arf in mouse and p14 ARF in human). As mentioned, germline mutations at this locus tend to be associated primarily with melanoma susceptibility, although with pancreatic cancer too in some families. Some such mutations affect both the p16 and ARF coding sequences, but a substantial fraction affect p16 only (Ruas and Peters, 1998; Sharpless and DePinho, 1999) . Conversely, a single melanoma-associated germline mutation was recently reported to affect ARF and not p16 (Rizos et al., 2001b) , while other ARF-only mutations have been found in sporadic melanomas (Rizos et al., 2001a) . Thus, INK4A and ARF can both apparently act as melanoma susceptibility genes, although more usually INK4A. The third such gene is CDK4, encoding cyclin-dependent kinase 4, the kinase that is inhibited by p16. Melanoma-associated mutations of both INK4A and CDK4 are found to disrupt p16-CDK4 binding (Ruas and Peters, 1998; Hayward, 2000) . Figure 1 shows the immediate cellular functions of p16 and CDK4, namely in regulating the activity of the retinoblastoma (RB) protein family, comprising RB1, another major tumor suppressor, and the two related proteins p107 and p130 (see Sage et al., 2000) . The RB family proteins are transcriptional regulators, of which the best-characterized function in the inhibition of proliferation is to suppress transactivation by the E2F family of transcription factors (Figure 1 ). The RB pathway appears critically important in the suppression of melanoma development, since all or nearly all human melanoma lines tested show disruption of this pathway, via p16 or RB1 deficiency, CDK4 mutation or overexpression of cyclin D1 (Bartkova et al., 1996; Walker et al., 1998) . ARF acts in a different pathway, namely by indirectly activating yet another key tumor-and growthsuppressor, p53. Protein Mouse double minute 2 (Mdm2, also called HDM2 in human), acts to reduce p53 abundance and activity, partly through ubiquitination of p53; Arf inhibits these actions of Mdm2 (for a review, see Sherr, 2001 ).
Molecular pathways in cellular senescence
To put in context the discussion of senescence in human melanocytes, we now introduce the concepts and models already derived from senescence of other human cell types, especially fibroblasts. These concepts have been reviewed at more length elsewhere (e.g. WynfordThomas, 1999; Artandi and DePinho, 2000) , and are summarized in Figure 2 .
Normal senescence in fibroblasts, occurring after about 40-70 population doublings (pd) in culture, has been called mortality stage 1 (M1). It appears to be mediated by both the RB and p53 pathways, since it can be circumvented by oncogenes that interfere with both pathways, including SV40 large T antigen or human papillomavirus (HPV)16 oncogenes E6 and E7. Significantly, M1 can also be circumvented by forced expression of the catalytic subunit of telomerase, human telomerase reverse transcriptase (hTERT). Telomerase is the enzyme found in the germline and some stem cells, which maintains the length of telomeres, the repetitive DNA at the ends of chromosomes. In most human somatic cells, which lack hTERT, the telomeres shorten progressively at each cell division (Artandi and DePinho, 2000; Blackburn, 2000) . Telomere shortening seems to evoke the proximal signal for M1 senescence, since M1 is prevented by maintaining telomere length (Figure 2 ). This signal apparently activates both p53 and RB family proteins (of which p107 and/or p130 are implicated in senescence as well as Rb1, at least in mouse cells; Sage et al., 2000) . p53 may be activated through a DNA damage response initiated by some telomere uncapping (Wynford-Thomas, 1999; Black- Figure 1 p16 and the RB pathway. See text for further explanation. Cyclin D represents a family of proteins, cyclins D1-D3. CDK6 has similar activity to CDK4, but it is CDK4 that appears important in melanoma, perhaps reflecting higher expression in pigment cells. RB represents the RB family. P: phosphorylation. E2F also represents a protein family; E2F proteins bind to DNA as homodimers, or heterodimers with DP1 or -2 proteins and transactivate a number of proliferation-related proteins, of which DNA polymerase a is one example. RB family proteins recruit histone deacetylases to the chromatin (not shown), which appear important in mediating the resulting transcriptional suppression burn, 2000) . There was some expectation that p53 activation in M1 senescence would be mediated by ARF, since there is extensive evidence that Arf is required for senescence in mouse fibroblasts (Kamijo et al., 1997; Sherr, 2001) . However, evidence to date suggests that ARF has little or no role in the senescence of human fibroblasts (Wei et al., 2001) . The RB-family activation in M1 is believed to be mediated by p16, because for example p16 expression is high in senescent cells, and because p16 alterations are frequent in cancer (Alcorta et al., 1996; Ruas and Peters, 1998; Sherr, 2001) . The implied link between telomere shortening and p16 elevation remains obscure; but there is evidence that an accumulation of transcription factor ETS1, which activates the p16 promoter, with a decline in ID1 which opposes the ETS1 action, mediate the increasing p16 level (Alani et al., 2001; Ohtani et al., 2001) (Figure 2 ). It remains to be determined how telomere shortening would lead to accumulation of ETS1 and loss of ID1.
Explantation
Where M1 is abrogated by interference with p53 and the RB family, fibroblast cultures proliferate, but eventually stop again in a phase called M2 or crisis (Figure 2 ). This is characterized not by proliferative arrest but by continuing division balanced by cell death. The cells are found to have acquired multiple chromosomal abnormalities. M2 appears to be caused by extreme telomere shortening, to the point where uncapping is frequent and the resulting exposure of DNA ends leads to cycles of end-to-end chromosome fusions followed by breakage during mitosis (Artandi and DePinho, 2000; Blackburn, 2000) . M2 as well as M1 can be bypassed in human fibroblasts by the expression of hTERT (Figure 2 ), leading to the indefinite growth known as immortalization.
Studies of senescence in human keratinocytes and other epithelial cell types gave evidence of a more rapid form of senescence, apparently mediated by RB family proteins without p53, since it could be blocked by the HPV16-E7 oncogene alone, after which the cells reached a stage resembling M1. This earlier senescence was designated M0 (Kiyono et al., 1998) (Figure 2 ). Cells that showed M0 arrest could be immortalized not by the expression of hTERT alone, but by hTERT with HPV16-E7 (Kiyono et al., 1998) . However, it was later reported that M0 was not obligatory in these cells, since if they were grown in the presence of fibroblast 'feeder cells', the lifespan was greater and senescence now resembled M1; moreover, the cells could be immortalized with hTERT alone (Ramirez et al., 2001) . It was suggested that M0 occurred because of inadequate culture conditions leading to 'stress'.
One more variant of human cell senescence should be mentioned, namely accelerated senescence seen when an oncogene such as activated RAS is expressed in normal cells (Serrano et al., 1997) (Figure 2 ). This has some similarities to M1, for example, interference with both the p53 and RB pathways is required to escape this arrest (Serrano et al., 1997) , and ETS activation of p16 has been implicated, but by ETS2 rather than ETS1 (Ohtani et al., 2001) . This form of senescence can still be induced in fibroblasts that have been immortalized with telomerase, but now appears to be mediated by p16 only, since it is not seen in p16-deficient human fibroblasts that are also expressing hTERT (Brookes et al., 2002) .
Senescence in cultured human melanocytes
Even if M0 in keratinocytes is an artefact of culture 'stress', there is evidence that senescence in different cell types can be effected in different ways (Wynford-Thomas, 1999) . There is direct evidence from mouse melanocytes for a difference from fibroblasts in control of senescence, as briefly discussed later. With human melanocytes, clearcut genetic comparisons are more difficult; nonetheless, there is mounting evidence for various differences from fibroblasts, as will now be discussed.
Culture conditions are clearly important in the timing of human melanocyte senescence, in that a wide range of lifespans has been reported by different research groups using different media and conditions, as reviewed previously (Bennett and Medrano, 2002) . These range from 8 to 90 pd for neonatal melanocytes, and from 2.4 to 40 pd for adult melanocytes (Eisinger and Marko, 1982; Gilchrest et al., 1984; Bennett et al., 1985; Graeven and Herlyn, 1992; Medrano et al., 1994; Haddad et al., 1998) . One factor affecting the lifespan appears to be the different mitogenic supplements used. Two common supplements used to stimulate growth are: (tetradecanoyl phorbol acetate (TPA), also called phorbol myristate acetate or PMA) and cholera toxin (CT). TPA transiently activates the protein kinase C enzyme family but chronically downregulates most PKCs. CT is one of a set of supplements that increase cellular cAMP signaling; others include melanocyte-stimulating hormone (MSH), theophylline, dibutyryl cAMP and isobutyl methylxanthine (IBMX). Comparisons between the two specific media led to the conclusion that lifespans of neonatal human melanocytes were shorter in a medium containing CT and IBMX (13-15 pd) than in the same basic medium without cAMP agonists but containing TPA (40-60 pd) (Medrano et al., 1994; Bandyopadhyay et al., 2001) . The cAMP agonists appeared more important than the TPA in producing this difference, since neonatal melanocytes grown with TPA as well as CT and dibutyryl cAMP were reported to grow for only about 12 pd (Halaban et al., 2000) . Direct comparisons using the same cell strains and medium simply with and without cAMP agonists seem to be lacking, but it can be provisionally concluded that human melanocyte lifespans are shortened by cAMP agonists, at least at high levels, as supported by comparison of available studies using different media (review: Bennett and Medrano, 2002) . Maximum lifespans reported by different authors for neonatal melanocytes are 8-45 pd where grown with cAMP agonists but 60-90 pd without; for adult melanocytes the maxima are from 2.4 to 10 pd with cAMP agonists, or up to 40 pd without.
If cAMP agonists increase the growth rate of melanocytes, why should they shorten lifespan? The answer may be connected with cell differentiation (here meaning the change from an immature precursor cell to a functional specialized cell, involving synthesis or activation of specialized proteins, and usually correlated in this lineage to the level of melanin synthesis). Stimulation of pigment cell differentiation by cAMP agonists is a long-studied topic (e.g. Wong and Pawelek, 1975; Halaban et al., 1983; Bennett, 1989; Haddad et al., 1999; Busca`and Ballotti, 2000) . Pathways include both stimulation of transcription of specialized melanocytic proteins (for reviews, see Busca`and Ballotti, 2000; Goding, 2000) and post-translational activation of the key melanosomal enzyme tyrosinase (Wong and Pawelek, 1975) . Human melanocytes approaching senescence show further increases in pigmentation and expression of some melanocytic proteins, even where already grown with cAMP agonists (Gilchrest et al., 1984; Medrano et al., 1994; Bennett et al., 1985; reviewed by Bennett and Medrano, 2002) . A similar increase in melanin content is seen in senescent mouse melanocytes, but not in Ink4a-Arf null mouse melanocytes at or after the same time in culture, indicating that it requires this locus; moreover, increased pigmentation of these cells was seen on restoring p16 without Arf (Sviderskaya et al., 2002) . It is plausible that the p16/RB pathway may promote melanocyte differentiation, since RB1 can bind to and possibly activate the transcription factor Mitf (Yavuzer et al., 1995) , which is central to the activation of melanocytic differentiation (see chapter by D Fisher). Possibly related to these findings is a recent report that growth of melanoma cells with cAMP agonists, including MSH, can activate p38, a mitogenactivated protein kinase (MAPK) also activated by cellular stresses including ultraviolet light, and can promote a dephosphorylation of RB1 that appears to require p38, although other steps in this pathway are not known (Smalley and Eisen, 2002) . This provides one possible link between cAMP stimulation of melanocytes, stress and acceleration of cellular senescence.
There has been some analysis of expression of CDKs and related proteins in human melanocytes senescing with and without cAMP agonists. Results were somewhat variable but it was concluded that p16 levels rose in both cases, with dephosphorylation of RB1 where tested, whereas levels of the p53-activated inhibitor p21 rose significantly only in the cells senescing without cAMP agonists (Haddad et al., 1998; Bandyopadhyay et al., 2001) . Accumulation of another CDK inhibitor p27 was observed in the presence of cAMP agonists (Haddad et al., 1998) . In our hands likewise, normal senescent melanocytes grown with cholera toxin among other factors showed high levels of p16 but not p21 (Sviderskaya et al., in press ). Low-passage human melanocytes were reported to express all the three RBfamily proteins: RB1, p107 and p130, while senescing melanocytes with cAMP agonists expressed predominantly RB1 and p130, both found in complexes with E2F proteins (Halaban et al., 2000) . It is not yet clear whether both RB1 and p130 had an active part in the senescence. Broadly speaking though, these findings are consistent with M0-like senescence in melanocytes grown with cAMP agonists, with a preliminary indication that p53 activation and a different pattern of senescence may occur following the longer lifespan seen without cAMP agonists.
Genetic analysis of human melanocyte senescence and immortalization
Evidence from the mouse indicates that genetic analysis and manipulation can be valuable in identifying distinctive features of melanocyte senescence. An interesting difference from fibroblasts was that a single copy of a deletion in the Ink4a-Arf locus, affecting both p16 and Arf, was reported to have no detectable effect on mouse fibroblast senescence (Serrano et al., 1996) , but did disrupt senescence in mouse melanocytes (Sviderskaya et al., 2002) . (As with fibroblasts, senescence was virtually absent in melanocytes homozygous for the same deletion; Sviderskaya et al., 2002.) Moreover, there was evidence for a more prominent role of p16 than Arf in mouse melanocyte senescence, unlike fibroblast senescence. For example, Arf was expressed by some immortal lines of mouse melanocytes, but p16 was never expressed (Sviderskaya et al., 2002) .
Turning to the human, two strains of human melanocytes with deletions or mutations impairing both copies of p16 but with wild-type ARF have recently been studied in culture, revealing some intriguing properties (Sviderskaya et al., in press ). Both strains showed substantially extended lifespans of around 50 pd in a medium with a cAMP agonist. In comparison, normal adult melanocytes show lifespans of no more than 10 pd in such media, as discussed above. Both p16-deficient strains showed elevation of the levels of p53 and p21 proteins at the time of senescence, whereas normal human melanocytes did not. Interestingly, both strains also showed excessive rates of apoptosis in a standard melanocyte medium, compared to normal human melanocytes. In both cases, however, this apoptosis was suppressed by coculture with keratinocytes, or with the keratinocyte products endothelin 1 and stem cell factor (Sviderskaya et al., in press ). One of the strains became aneuploid during culture, but the other remained diploid and senesced without dicentric chromosomes or other chromosomal aberrations. Both strains could be immortalized readily by retroviral transduction of exogenous hTERT, whereas three strains of normal human melanocytes grown under the same conditions could not, even when grown with feeder cells (Sviderskaya et al., in press ). Thus, it appeared that p16-deficient melanocytes did not show the M0-like senescence characteristic of normal human melanocytes under these conditions, but a longer lifespan followed by M1-like senescence (or an M2-like arrest in one strain that spontaneously became aneuploid). This provided strong evidence that p16 is required for human melanocyte senescence on schedule, under culture conditions normally regarded as favorable, while the p53 pathway can mediate a secondary form of senescence more like that of fibroblasts. As another comparison, p16-deficient dermal fibroblasts cultured from one of the same individuals showed no major extension of lifespan, no evidence of excessive apoptosis and did not become aneuploid (Brookes et al., 2002) .
Other work on the immortalization of human melanocytes has been reported. Zepter et al. (1995) found that the expression of SV40 large T antigen was not sufficient to immortalize these cells (not surprisingly, as telomere shortening would not be prevented). Conversely, it was surprising that HPV16-E6 and E7 oncogenes were reported to be sufficient to immortalize two strains of human melanocytes (Le Poole et al., 2000) , since these are expected to have an action similar to SV40 large T antigen, inactivating both p53 and the RB family but having no effect on telomerase. However, the latter authors did not test their cells for chromosomal aberrations, nor for spontaneous telomerase activation, so it is possible that the immortalization was associated with additional spontaneous genetic change. Bandyopadhyay et al. (2001) reported a major extension of lifespan of normal melanocytes (grown with cAMP agonists) using hTERT alone. This too seems surprising since the p16/RB pathway was not manipulated; however, the hTERT-treated cells showed a number of changes in protein expression including reduced levels of p16 (Bandyopadhyay et al., 2001 ). It is thus again possible that additional spontaneous genetic or epigenetic changes took place in these cells, as with the spontaneous silencing of p16 by methylation sometimes observed in normal human mammary epithelial cells (Kiyono et al., 1998) . These data are consistent with the idea that disruption of the p16/RB pathway as well as telomerase activation are needed for immortalization of melanocytes. This idea is attractive as a rationale for why INK4A and CDK4 are melanoma susceptibility genes.
Melanocyte senescence in vivo -the mole?
Is the M0-like, p16-dependent senescence observed in human melanocytes an artefact of culture stress, and therefore of no importance? The key question seems to be, whether this kind of growth arrest has any relevance to carcinogenesis in vivo. This is not out of the question; cell proliferation in a solid tissue may be very slow, and far from 'optimal'. We will therefore now consider whether senescence of melanocytes can be observed in vivo, and the relevance of p16 to this.
Humans with germline p16 mutations may expect to develop one or a few cutaneous melanomas in their lifetime. In many families, they will also develop a large number of benign nevi or moles, which are considered potential precursors of melanoma (Hayward, 2000) . Thus, p16 appears to have a role in controlling the growth of moles. Moles in one individual can have a variety of different colors and sizes, suggesting that they are clonal. Thus, a mole appears to be a clonal proliferation of melanocytes that have all stopped growing for some reason. One obvious possible reason is cellular senescence. Some growth-stimulatory mutation may evoke the initial proliferation. RAS mutations, for example, have been reported in some kinds of nevi (e.g. Papp et al., 1999) . This could over-ride whatever limits the normal cellular spacing of melanocytes.
Melanocytes in nevi are more closely packed together than in normal skin (Mooi and Krausz, 1992) , and some reduction in growth-factor dependence in culture has been reported (Herlyn et al., 1985; Halaban et al., 1986) . The cells in vivo apparently cease growing and the nevus remains static, or regresses in old age.
Further support for the idea that moles are senescent clones comes from a variety of observations. Cultures of melanocytes from nevi tend to have particularly limited (albeit variable) lifespans in culture, as reviewed previously (Bennett and Medrano, 2002) . The primary cultures are variable in morphology, not surprisingly, as the cultures are likely to include some normal melanocytes. They can however include unusually large, stellate, well-pigmented and/or binucleate cells (Herlyn et al., 1985; Halaban et al., 1986) , all properties seen in senescent melanocytes. Telomerase activity is low or absent in benign nevi, while present in most melanomas and some dysplastic nevi (Glaessl et al., 1999; Rudolph et al., 2000) . Moreover, p16 is expressed in nevi, but often at a lower level in primary melanomas (KellerMelchior et al., 1998) , lesions that grow progressively.
Are the sizes of moles consistent with the expected number of doublings for a senescent clone? This is hard to answer, given that the melanocyte lifespan depends on the environment. It seems reasonable to assume that there is some cAMP stimulation in vivo, since the MSH receptor (MC1R) acts through this pathway, and does affect skin color . In culture, melanocyte lifespan in the presence of cAMP agonists falls sharply from up to 45 pd in neonatal melanocytes to no more than 10 pd in adult melanocytes (see above). These figures would gives clones of around 3 Â 10 12 and 1 Â 10 3 cells, respectively. Most normal nevi probably contain between about 10 3 and 10 7 cells , while congenital nevi do tend to be larger than others. Given the unknown cellular environment in vivo, and that humans are generally not neonatal by the time early nevi stop growing, the figures seem reasonably compatible. 'Oncogenic stress' could also reduce the proliferative lifespan in some cases. Interestingly, in relation to a possible role of cAMP in senescence, children with MC1R mutations tend to develop two other kinds of static, benign melanocytic lesions: ephelides or freckles, and solar lentigines . Moreover MC1R mutations are a risk factor for melanoma; this has been hypothesized to be because of increased ultraviolet mutagenesis in skin because of the associated low pigmentation and deficient suntanning, but was recently reported to be independent of skin color (Kennedy et al., 2001) .
Immortalization, apoptosis and melanoma progression
If moles may be related to melanocyte senescence in vivo, what may be the equivalent of melanocyte immortalization in vivo? By definition, a lesion that grows progressively is a neoplasm. The earliest neoplastic melanocytic lesion is the radial growth phase (RGP) or superficial spreading) melanoma, which spreads within or just beneath the epidermis (Clark et al., 1989) . In this relation, it is interesting that deficiency in the RB pathway as well as hTERT activation appears necessary for melanocyte immortalization, and that p16-deficient human melanocytes with active ARF show a high rate of apoptosis that is suppressed by keratinocytes or their products (Sviderskaya et al., in press ). Thus, it may be speculated that RGP melanoma cells can grow only in or near the epidermis because they have a deficiency in p16 or the RB pathway, to become immortal, but little other genetic change. Therefore, they require keratinocytes or their products for survival (Figure 3) , like p16-deficient melanocytes. Moreover, if an RB pathway deficiency is required for melanoma initiation, it can potentially explain why INK4A and CDK4 are susceptibility genes for melanoma.
A corollary (Figure 3 ) is that the next stage of progression, the vertical growth phase (VGP) or nodular melanoma, which grows and invades deep into the dermis and is competent for metastasis (Clark et al., 1989) , would require some lesion repressing apoptosis, and thus allowing the cells to survive in the absence of keratinocytes. Interestingly, among the genetic alterations consistently reported in advanced melanomas, many of them are indeed of a type expected to reduce apoptosis. These include PTEN loss, which would inhibit apoptosis via AKT activation; overexpression of a number of protein tyrosine kinases or RAS activation (both of which would also activate AKT), b-catenin activation (reviews Easty and Bennett, 2000; Halachmi and Gilchrest, 2001 ) and the newly reported BRAF mutations (Davies et al., 2002) . (These have speculatively been placed at an earlier stage in Figure 3 however, because of their high reported frequency in melanoma cells.) If such an alteration in apoptotic rate preceded immortalization, in a given lesion, then after immortalization one might expect development of a nodular/ VGP melanoma without an RGP melanoma, as does indeed occur in some cases. Other variations in cutaneous melanoma development could similarly arise through these three basic alterations occurring in a different order. The dysplastic nevus, not always seen prior to melanoma, may be equivalent to an intermediate stage in immortalization such as M2/crisis (Figure 3 ).
In conclusion, it seems likely that melanocyte immortalization is a mandatory step in early melanoma development, requires both telomerase activation and deficiency of the p16/RB pathway, and may be equivalent to the initiation of a melanoma, usually an RGP melanoma. Figure 3 incorporates these ideas into a preliminary genetic model for the best-known stages of primary melanoma progression, consistent with available evidence, although the evidence is not complete. The model has a number of testable features, such as that a difference in survival without keratinocytes would be seen consistently between RGP and VGP melanoma cells. The high visibility and accessibility of cutaneous melanoma and its precursors makes this an ideal system for the testing of such genetic models for progression, raising the hope that melanoma may be one of the first solid tumors for which the minimal genetic requirements for malignancy may be definitively resolved. 
